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Hydrogen Bonding Interactions in the Binding of Aricept® with the Enzyme Acetylcholinesterase
Abstract:
The anti-Alzheimer’s drug Aricept® was docked into a computer model of the enzyme 
acetylcholinesterase using the Amber force field mode of HyperChem 7.5 Professional.  The 
importance of hydrogen bonding within the active site gorge was investigated by systematically 
mutating tyrosine and serine to phenylalanine and alanine, respectively.  Two amino acids within the 
active site gorge, Tyr 130 and Ser 81, showed less favorable binding in the absence of the hydroxyl 
group.
Introduction:
Alzheimer’s is a progressive, degenerative disease of the brain that affects more than 5 million 
Americans.  Alzheimer’s disease is marked by gradual and irreversible declines in cognitive 
functions, including memory, communication skills and the ability to learn new material.  The 
cognitive impairments typically associated with this disease suggest dysfunction in the cholinergic 
system.  Recent efforts in the treatment of Alzheimer’s have focused on the inhibition of 
acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine.  The hydrolytic 
function of this enzyme occurs at the base of a 20 Ǻ deep active site gorge.  With the inhibition of 
the enzyme, higher levels of acetylcholine are available to the brain. 
Methods:
The structure of Torpedo californica acetylcholinesterase complexed with Aricept® was obtained 
from the NIH Protein Data Base.  Using the molecular modeling program HyperChem 7.5 
Professional, docking studies of Aricept® with acetylcholinesterase were completed.  The amino 
acid residues tyrosine and serine were systematically mutated to phenylalanine and alanine, 
respectively, in order to determine the relative importance of each hydroxyl group in the docking of 
Aricept® with acetylcholinesterase.  After each mutation, the Amber force field was used to 
calculate the theoretical binding energy.  By comparing these values to the value of the un-
mutated enzyme, it was possible to infer which hydroxyl groups are particularly important in the 
stabilization of the acetylcholinesterase-Aricept® complex.
Results:
The active site gorge contains 5 tyrosine residues and 5 serine residues, as well as about 20 
additional amino acids.  Tyr 130 and Ser 81 were the only two residues that showed less 
favorable binding energies when mutated to phenylalanine and alanine, respectively. 
Discussion:
When amino acids are mutated, the complex becomes either more stable (- ΔG) or less stable 
(+ ΔG).  The differences in binding energies are caused by a combination of factors including 
hydrogen bond interactions and sterics.  In the cases where more favorable binding occurs in 
the absence of a hydroxyl group, it is likely that the steric hindrance caused by the oxygen plays 
a larger role than do the attractive forces of the hydrogen bond interactions.  Another possible 
explanation could be that the hydrogen bond forces are strong enough so as to prevent the 
amino acids from acquiring more stable conformations, ones that they are able to adapt in the 
absence of the constraints caused by hydrogen bonding.
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Amino Acid Mutated Mutated to:          ΔG Cycles Points 
No mutation N/A 0 1088 2362 
Ser 200 Ala -93.313 1087 2307 
Ser 81 Ala +181.501 822 1766 
Ser 124 Ala -126.788 989 2062 
Ser 286 Ala -156.55 954 1998 
Ser 122 Ala -181.046 1144 2378 
Tyr 70 Phe -49.578 955 2016 
Tyr 442 Phe -46.226 930 1966 
Tyr 334 Phe -92.526 944 2006 
Tyr 121 Phe -118.086 930 1964 
Tyr 130 Phe +24.42 1030 2177 
 
Force Field Energy Cycles Points Time 
Amber -8471.793 1088 2362 20 hrs 
Opls -31795.8 4384 9913 22 hrs 
MM+ -5072.19 937 2164 49 hrs 
Bio CHARMM -2264.4 1344 2831 21 hrs 
